Neelam Sharma, MS; Lakshmi Lavanya Kundurthy, BE; and Hemant N. Joshi, PhD, MBA*- Tara Innovations, LLC, www.tara-marketing.com. *[email protected]
Crude Drug Composition for Preventing or Treating Respiratory Diseases;
M.W. Son, M.J. Bae, W.W. Lee, and D.S. Lee; Helixmith Co., Seoul, KR; U.S. Patent # 11,559,555; January 24, 2023
Respiratory diseases affect airways and lungs and eventually, respiration. Existing respiratory medicines fail to delay or stop the progression of respiratory disease through removal of the fundamental cause of respiratory disease. There is an urgent need to develop novel medicines for preventing and treating respiratory diseases, which are more diverse and complex. This patent relates to herbal medicine compositions for prevention, treatment or alleviation of a respiratory diseases. Composition comprises of a mixed extract of two or more selected from the group consisting of Brassicae semen extract, an Adenophorae radix extract, a Lonicerae Folium extract and Perillae semen extract. Inventors of the patent have verified that complex medicine herbal extracts inhibits infl ammation, aging, lung tissue damage, and it provides an antioxidative effect.
Natural Killer Cells;
H.J.M. Brady and M. Fuchter;Imperial College of Science, Technology and Medicine, London, GB; U.S. Patent # 11,559,547; January 24, 2023
Natural Killer (NK) cells have a critical role in the immune system where they destroy cancerous, damaged cells. NK cells can be identified by the presence of CD56 (NK adhesion molecule) and the absence of CD3 (CD56+, CD3−). Existing therapies are not very successful in terms of their efficacy. The present inventors have worked to identify drugs that can increase NK cell numbers. This invention provides an ex vivo method of expanding NK cell population by a) culturing a hematopoietic progenitor cell (HPC) sample obtained from patient. b) contacting said sample with a compound, which inhibits the action of REV-ERB. C) expanding said cells in vitro to produce NK cell population.
Systems and Methods to Improve Vaccine Efficacy;
S. Matthias; Fred Hutchinson Cancer Center, USA; U.S. Patent # 11,566,061; January 31, 2023.
Vaccines are used to stimulate the body’s immune response against diseases. Vaccines can consist of weakened, killed, or fragmented microorganisms or toxins or other biological preparation, such as antibodies or mRNA (messenger RNA). When a vaccine is administered, APC (antigen-presenting cell) takes up the antigen and presents it to B cells or T cells to elicit the immune response. B cells that express the receptors specific to presented antigen will produce antibodies. Effectiveness of B cell immunity is limited to extracellular pathogens. Pathogens that exist intracellularly and those bound to cell surfaces are not as susceptible to B cell antibodies, they require T-cell-mediated immunity. At present, there are no reliable vaccines, which can be used to treat infectious disease and cancer that require T-cell-mediated immunity. This patent provides systems and methods to increase the efficacy of vaccines that require T cell-mediated immunity. Methods utilize polynucleotides that genetically modify T cell to express a T cell receptor specific for an administered vaccine antigen.
Nanovesicles Derived from Enhydrobacter Bacteria, and Use Thereof;
Y.K. Kim; MD Healthcare, Inc., Seoul, KR; U.S. Patent # 11,554,144; January 17, 2023.
Most bacteria release membrane vesicles (MVs) that contain specific cargo molecules and have diverse functions. This patent describes a composition comprising an effective number of vesicles derived from Enhydrobacter aerosaccus to suppress inflammation. The human body has 10 times more bacteria than human cells. Bacteria secrete nanometer-sized vesicles in order to exchange information on genes, proteins, and other compounds. These vesicles can cross the mucous barrier and enter cells. The inventors confirmed that the contents of vesicles derived from Enhydrobacter bacteria significantly decreased in samples obtained from patients with various kinds of cancers and other diseases. Also, macrophages treated with these vesicles, IL-6 and TNF-α secretion mediated by pathogenic vesicles was significantly inhibited.
Treatment Methods Using DNA Editing with Single-Stranded DNA;
C. B. Gurumurthy, H. Miura, and M. Ohtsuka; Board of Regents of the University of Nebraska, USA, and Tokai University Educational System, Japan; U.S. Patent # 11,549,126; January 10, 2023.
This patent discloses compositions, methods and kits for DNA editing using single-stranded DNA. It also describes compositions and methods for modifying gene expression using artificial microRNAs. The patent describes methods for modifying a target DNA sequence in a cell. It may include: (a) introducing a single-stranded DNA in the cell, and (b) introducing or expressing a nuclease system in the cell, wherein the nuclease system cuts the target DNA sequence. Another kit may include one or more RNA polymerase, a reverse transcriptase, an RNA-degrading enzyme and a nuclease system. The single-stranded DNA kits may be over 100 bases.
Continuous Administration of Pharmaceutical Composition for Treatment of Neurodegenerative Disorders;
R. Bolsoy; Intrance International AB, Uppsala, SE; U.S. Patent # 11,547,689; January 10, 2023.
Neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease might not be cured as neurons once killed are not replaced by new neurons. In people suffering from Parkinson’s disease, the dopamine level drops. Dopamine as a drug is not effective as it does not cross the blood-brain barrier (BBB). Levodopa is a precursor of dopamine and can cross the BBB. This patent presents a composition comprising a dopamine replacement agent, a dopamine decarboxylase inhibitor, and a catechol-O-methyltransferase inhibitor. The first dosage is 20-35% of the total daily dosage of the dopamine replacement agent. The second dosage adds up to the total daily dosage of dopamine replacement agent.
Compositions and Formulations for Treatment of Malignancies;
Y. Kew; Neugate Pharma, USA;U.S. Patent # 11,559,500; January 24, 2023.
Malignant tumors are capable of invading into adjacent tissues, or to distant tissues. The invention provides formulation compositions and methods of treatment of malignancies via activation of an inflammatory response in the subject. Such compositions can also be administered along with other treatments such as chemotherapy or radiation therapy. In an immune modulating system, the following components were used – a histamine H2 receptor antagonist, an adenosine 2A receptor inhibitor, and a non-steroidal anti-inflammatory drug. Another composition increases the IL-15 expression associated with an increase in the antibody-dependent cellular cytotoxicity of natural killer cells or with an increase in the cytotoxic T lymphocyte activity.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!